SE8700466L - VACCINES MOTHER MELANOM - Google Patents

VACCINES MOTHER MELANOM

Info

Publication number
SE8700466L
SE8700466L SE8700466A SE8700466A SE8700466L SE 8700466 L SE8700466 L SE 8700466L SE 8700466 A SE8700466 A SE 8700466A SE 8700466 A SE8700466 A SE 8700466A SE 8700466 L SE8700466 L SE 8700466L
Authority
SE
Sweden
Prior art keywords
peptides
proteins
melanom
vaccines
mother
Prior art date
Application number
SE8700466A
Other languages
Unknown language ( )
Swedish (sv)
Other versions
SE8700466D0 (en
SE506024C2 (en
Inventor
J P Brown
C D Estin
G D Plowman
T M Rose
K E Hellstrom
I Hellstrom
A F Purchio
S-L Hu
S Pennathur
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26676698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE8700466(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/007,230 external-priority patent/US5262177A/en
Application filed by Oncogen filed Critical Oncogen
Publication of SE8700466D0 publication Critical patent/SE8700466D0/en
Publication of SE8700466L publication Critical patent/SE8700466L/en
Publication of SE506024C2 publication Critical patent/SE506024C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Peptides or proteins which belong to a melanoma-associated antigen are described. These are prepared in large amounts using recombinant DNA techniques and/or chemical synthetic methods. The peptides or proteins can be used as immunogens in vaccine formulations which elicit an immune response able selectively to destroy melanoma cells in a vaccinated individual. When the peptides or proteins are expressed by a recombinant virus, it is possible to prepare vaccine formulations based on inactivated viruses or based on live viruses.
SE8700466A 1986-02-07 1987-02-06 Melanoma-associated P97 antigen and immunogenic composition SE506024C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82731386A 1986-02-07 1986-02-07
US07/007,230 US5262177A (en) 1986-02-07 1987-01-27 Recombinant viruses encoding the human melanoma-associated antigen

Publications (3)

Publication Number Publication Date
SE8700466D0 SE8700466D0 (en) 1987-02-06
SE8700466L true SE8700466L (en) 1987-08-08
SE506024C2 SE506024C2 (en) 1997-11-03

Family

ID=26676698

Family Applications (2)

Application Number Title Priority Date Filing Date
SE8700466A SE506024C2 (en) 1986-02-07 1987-02-06 Melanoma-associated P97 antigen and immunogenic composition
SE9202934A SE9202934D0 (en) 1986-02-07 1992-10-07 VACCINES AGAINST MELANOM

Family Applications After (1)

Application Number Title Priority Date Filing Date
SE9202934A SE9202934D0 (en) 1986-02-07 1992-10-07 VACCINES AGAINST MELANOM

Country Status (18)

Country Link
JP (3) JP2664673B2 (en)
BE (1) BE1000175A3 (en)
CH (1) CH675424A5 (en)
DE (1) DE3703702C2 (en)
DK (1) DK63287A (en)
ES (2) ES2012815A6 (en)
FI (1) FI94836C (en)
GR (1) GR870195B (en)
HU (1) HU209144B (en)
IE (1) IE59597B1 (en)
IT (1) IT1222359B (en)
MX (1) MX9203574A (en)
NL (1) NL8700285A (en)
NO (1) NO178931C (en)
NZ (1) NZ219192A (en)
OA (1) OA08478A (en)
PT (1) PT84255B (en)
SE (2) SE506024C2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19821925A1 (en) * 1998-05-15 1999-11-18 Roehnisch Tim Bacteriophage expression system for production of composition for induction of tumor specific responses
JP4414023B2 (en) * 1999-08-05 2010-02-10 オリエンタル酵母工業株式会社 Method and reagent for measuring arthritis-related melanotransferrin
JP4708027B2 (en) * 2002-10-01 2011-06-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Anti-cancer compositions and anti-infective disease compositions and methods of using them
US8207314B2 (en) * 2003-05-16 2012-06-26 Sanofi Pasteur Limited Tumor antigens for prevention and/or treatment of cancer

Also Published As

Publication number Publication date
FI870501A (en) 1987-08-08
HUT43107A (en) 1987-09-28
NO870475L (en) 1987-08-10
DK63287A (en) 1987-08-08
FI870501A0 (en) 1987-02-06
SE8700466D0 (en) 1987-02-06
DE3703702C2 (en) 1997-07-10
NO870475D0 (en) 1987-02-06
SE9202934D0 (en) 1992-10-07
CH675424A5 (en) 1990-09-28
IE870319L (en) 1987-08-07
FI94836C (en) 1995-11-10
ES2012815A6 (en) 1990-04-16
ES2017258A6 (en) 1991-01-16
GR870195B (en) 1987-06-10
MX9203574A (en) 1992-07-01
HU209144B (en) 1994-03-28
JP2664673B2 (en) 1997-10-15
DE3703702A1 (en) 1988-02-18
NZ219192A (en) 1991-10-25
JPH09135692A (en) 1997-05-27
FI94836B (en) 1995-07-31
JPH08280390A (en) 1996-10-29
OA08478A (en) 1988-07-29
NO178931C (en) 1996-07-03
NO178931B (en) 1996-03-25
BE1000175A3 (en) 1988-07-12
IT1222359B (en) 1990-09-05
JPS62294698A (en) 1987-12-22
IT8719291A0 (en) 1987-02-06
DK63287D0 (en) 1987-02-06
NL8700285A (en) 1987-09-01
PT84255B (en) 1989-11-30
SE506024C2 (en) 1997-11-03
PT84255A (en) 1987-03-01
IE59597B1 (en) 1994-03-09

Similar Documents

Publication Publication Date Title
ATE97164T1 (en) RECOMBINANT VACCINIA VIRUS MVA.
DK0584348T3 (en) Genetic vaccine against immunodeficiency viruses
ATE258188T1 (en) RETRO, INVERSO, AND RETRO-INVERSO SYNTHETIC PEPTIDE ANALOGS
EE9900343A (en) Synthetic Polynucleotide, Immune Response Method, Immunogenic Composition, Anti-HIV Immune Response Induction Method, Antigen-Inducing Cell Indication, and Pharmaceutical Composition
NO863803L (en) Vaccines and Immunoassays for Acquired Immunodeficiency Syndrome (AIDS).
DK84195A (en) Vaccine to produce an immunogenic response
FI102382B1 (en) Expression system for chimeric glycoproteins containing immunogenic fragments of human respiratory syncytial virus glycoproteins
ATE105334T1 (en) CHIMAERIC GLYCOPROTEINS CONTAINING IMMUNOGENIC SECTIONS OF HUMAN PARAINFLUENZAVIRUS TYPE 3.
DK0909323T3 (en) Helicobacter pylori bacterioferritin
DE3689622D1 (en) Vaccines against human respiratory viruses.
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
ATE73349T1 (en) HEPATITIS SURFACE ANTIGEN PARTICLE VACCINATION.
SE8700466L (en) VACCINES MOTHER MELANOM
AR009365A1 (en) FMD VIRUS VACCINES (FMDV), PEPTIDES, DNA SEQUENCES AND THE USE OF PEPTIDES IN DETECTION SYSTEMS AND THE USE OF FMDC VACCINE FOR PREPARATION OF A COMPOSITION TO IMMUNIZE PIGS AND CATTLE
KR900701291A (en) Vaccines and diagnostic tests for hemophilus influenza
NZ213303A (en) Plasmodium protein, dna sequence and vaccine
DE69428984D1 (en) VIRAL PROTEIN IMMUNE RESPONSE
DE60239753D1 (en) VACCINATE AGAINST INFECTIOUS LACHSANEMIA VIRUS
DE69637435D1 (en) SAPONIN COMPOSITIONS AND ITS USE
BR9306187A (en) Bacterin-toxoid vaccine pasteurella haemolytica type a-1
RU95122782A (en) PHARMACEUTICAL PREPARATIONS CONTAINING NUCLEIC ACIDS
EP0293201A3 (en) Method of vaccination for hepatitis b virus
Pauksen B and T cell immunity after bone marrow transplantation: Studies with special reference to measles immunity.
RU92004487A (en) DNA, POLIPEPTID, VACCINE, VECTOR, MICROORGANISM, INSECTED CELL, REAGENT, METHODS OF TREATMENT AND PREVENTION, METHOD OF DETECTING ANTIGENES

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 8700466-9

Format of ref document f/p: F